New clinical trial to explore DMT as treatment for substance use disorders

The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT.

Psychedelic Schools for ‘Shamans’ Are Popping Up Like Mushrooms

Even before Oregon and Washington, D.C., decriminalized medical psilocybin, the active ingredient in “magic mushrooms,” in November, a market was emerging for schools that teach mental and medical health professionals how to use psychedelics in their treatment.